Company Overview and News
The string of successive positive weeks for midstream ended this week. Midstream stocks were down roughly 1% across MLP and midstream indexes. Canadian Midstream stocks outperformed for the first time in a while. Utilities had a very strong week and the S&P was slightly positive. Oil prices continue to languish, now down 7 straight weeks, while natural gas prices continue to hold firm.
TGE CQP AMID PAGP ENB CEQP HCLP KMI HESM DKL TRP EBBNF OKE PAA ED KMR CVB NEE ENBBF TRP KEYUF LNG GLPRU ENLC ENB GBNXF ETP GLP SEMG TRGP KMRFZ
Good day. My name is Jack, and I’ll be your conference operator today. At this time, I would like to welcome everyone to the Keyera Corp. Second Quarter 2018 Results. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you.
Midstream traded up for a 6th straight week, with MLPs again out front with a 2.2% total return. The MLP Index's YTD total return is now nearly 12% after being negative less than a month ago. The broad market struggled a bit, and midstream was a safe place to hide on Friday when the broad market sold off on Turkey's currency plunge.
KAAC APA KEYUF XOM SMLP IPL GBNXF EQT KMI EQGP PAA KMR PBA NFG IPPLF CVB KMRFZ FANG
Midstream made gains for a 5th straight week, again led by MLPs. It was the best week for the MLP Index since January 2017. Good vibes and momentum carried through from last week with strong results from EPD, OKE and ENB among others, punctuated by the earlier than expected ETE/ETP simplification. After this week's move, the MLP Index has produced total return of 11.3% since June 25th.
ENB TRP KEYUF TRP ENB PBA IPPLF IPL
The month of July only saw one Canadian Dividend All-Star, Alimentation Couche-Tard, announce a dividend increase. Fret not, the summer lull is about to come to an end. It all begins this week where two All-Stars are expected to raised dividends. There are several others overdue for a raise who are also scheduled to report earnings.
RBA TRI SAPIF ANCUF HDIUF ANCTF KEYUF FSZ CIFAF ATD.A ATD.B KEY CIX RBA TRI
Midstream and MLPs traded well this week, but not as well as you'd expect given a 5%+ oil move and strength in income securities (like utilities). The OPEC meeting Friday turned out to be a catalyst despite no surprise, because of how well-managed expectations were. Oil, energy stocks and MLPs were sharply higher Friday, and the Dow finished positive for the first time in 9 days.
ARLP OMP CQP ENB NSH KMI CAPL KMR CVB TRP LNG SRLP ETP SHLX NRP ENBL NS CQH PBA BKEP ETE PAGP WGP TEP TEGP CEQP TRP AMGP OKE PAA KEYUF ENLK OCIP TCP DM SRE KMLGF CVRR SEMG TRGP KMRFZ
Midstream and MLPs synched up this week to rally 2.7%, outperforming the S&P 500 and utilities, despite renewed oil price angst this week. Midstream stocks and MLPs resumed their recovery after last week's pause, and have now posted gains in 7 of the last 10 weeks. After bottoming in late March, the AMZ and AMEI have posted total returns of 16.2% and 12.3%, respectively. The rally has helped the MLP Index break back into positive territory year-to-date, and the MLP Index closed the week almost exactly at its 200-day moving average (269.
NGL CQP CVI ENB TGP NSH KMI WMB EBBNF KMR CVB TRP LNG ENB ETP GMLP GLP ENBL NS PBA PAGP EPD WGP SPB CEQP TRP AMGP OKE PAA ENBBF KEYUF ENLK ENLC TCP DM CVRR SEMG KRP SUUIF KMRFZ
Kinder Morgan Canada (OTCPK:KMLGF)[TSX:KML] and its parent company Kinder Morgan (KMI) announced they have sold their Transmountain pipeline project along with its planned expansion to the Government of Canada for $4.5 billion Canadian dollars. This eliminates essentially all of the risk associated with the project for the company, and allows it to recoup its sunk costs. It also eliminates its biggest driver of growth.
KML KEYUF KMI KMR KMRFZ CVB
Midstream traded down and underperformed utilities (+3.2%) and the S&P 500 (+0.3%), with oil price declines offering a reason for midstream to pause following a very strong couple of weeks for oil, energy and midstream. Considering XLE was down 5.5% and oil dropped 5%, midstream held up pretty well, benefiting from its considerable income component in a good week for Treasuries and utilities.
SN MPLX TRP APA CQP KEYUF LNG SCAZP KMI TRP KMR SNZYP TRGP CVB KMRFZ
Midstream overall outperformed and MLPs again led the way, up another 3.1%. The MLP Index is now up 14.4% the last 8 weeks, rallying in 6 of those 8 weeks. Energy and oil prices continue to trade well, with MLPs trying to keep pace with broad energy stocks. News flow was light until Thursday's simplification party. Weaker Canadian and utility performance dragged down the broader AMEI midstream index performance.
TRP CQP KEYUF LNG BWP EPE ENB SEP BPL WPZ KMI NRP TRP GLP EEP KMR CVB KMRFZ
Midstream resumed gains this week, with similar gains across MLPs, U.S. and Canadian corps. Oil and the broad stock market rallied as well. No surprise, but $70/bbl seems to be a positive for energy stocks broadly. Midstream-specific sentiment has also benefitted from solid earnings season that included baby steps towards resolution of pending simplifications, de-leveraging, etc. The MLP Index is just one more good week away from being flat for the year (including distributions).
DCP NBL KEYUF BWP ENB ANDV L ANDX ENB SHLX WMB SEMG ENBL
After an extremely busy week last week, there are only two Canadian Dividend All-Stars scheduled to report earnings this coming week. Unfortunately, neither are expected to increase dividends. However, we have plenty to catch up on from last week before banks start to report in two weeks.
FINGF FNV.WT.A LSDAF FNV KEYUF OTEX CIFAF FTT T LAS.A WN AQN OTC ONEXF KEY CIX TU FNV
Good morning. My name is Lisa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Keyera Corp. First Quarter 2018 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you.
KEYUF KMI KMR KMRFZ CVB
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET